White Paper

Manufacturing Cell Therapies
Development Strategies for Commercial Vision

Developing and manufacturing a patient-specific cell therapy (PSCT) from clinical trials to a commercial product presents unique challenges.

In this white paper, Richard Grant, Global VP of Cell Therapy at Invetech, and Brian Hampson, VP of Manufacturing Development & Engineering at PCT, share their unique insights on the topic, including how to:

  • Discover manufacturing equipment and strategies that maximize quality, scalability, and sustainability
  • Improve cost-effectiveness and commercial viability
  • Reduce the need for a large up-front investment by integrating and automating patient-specific cell therapy processes
  • Define a Quality Target Product Profile for your cell therapy product early in development
  • Understand the importance of communication and the characteristics of a successful relationship between a cell therapy developer and a contract development and manufacturing organization (CDMO)

Download the Guide

Let’s create tomorrow’s cell and gene therapy solutions

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate vital, emerging therapies from the clinic to commercial-scale manufacturing. Together with our partners, we expand the reach of next-generation medical advances that are revolutionizing healthcare. Learn more at invetechgroup.com

Organovo logo-2
Humacyte logo-2